机译:接受一线免疫治疗组合治疗的患者转移性透明细胞肾细胞癌二线治疗后的无进展生存期
Department of Medicine Memorial Sloan Kettering Cancer Center;
Department of Radiology Memorial Sloan Kettering Cancer Center;
Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center;
Immunotherapy; Progression-free survival after second line of therapy; Renal cell carcinoma; Tyrosine kinase inhibitor;
机译:Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy
机译:Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient
机译:Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria
机译:Purkinje Cell Survival需要TTBK2和初级纤毛
机译:Engaging the Gene and Cell Therapy Community in China: 一步一个脚印
机译:Overexpression of Foxm1 is associated with tumor progression in patients with clear cell renal cell carcinoma